# FDA recall D-0290-2026

> **Cipla USA, Inc.** · Class II · drug recall initiated 2026-01-02.

## Product

Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059.  NDC:  69097-870-67

## Reason for recall

Presence of Particulate Matter.

## Distribution

Nationwide in the USA

## Key facts

- **Recall number:** D-0290-2026
- **Recalling firm:** Cipla USA, Inc.
- **Classification:** Class II
- **Product type:** drug
- **Status:** Ongoing
- **Initiation date:** 2026-01-02
- **Report date:** 2026-01-21

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Warren, NJ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0290-2026

## Citation

> AI Analytics. FDA recall D-0290-2026. Retrieved 2026-06-09 from https://api.ai-analytics.org/recall/D-0290-2026. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*